BridgeBio Pharma, Inc. (BBIO) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2025-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2025-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2025-06-30..
Borrowing debt
Overview →Financial period ending 2025-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2025-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2025-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2025-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 756.89M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.08B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | (m) | (m) | (m) | $0.00 | (m) | $756.89M | $1.08B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $881.64M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $437.34M | (m) | (m) | $919.34M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $436.22M | (m) | (m) | $664.98M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $435.45M | (m) | $447.77M | $794.38M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $434.72M | (m) | $519.69M | $849.33M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $446.44M | (m) | $375.94M | $546.38M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $441.72M | (m) | $505.21M | $655.01M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $440.50M | (m) | $333.31M | $503.66M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $435.76M | (m) | $441.49M | $625.68M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $430.99M | (m) | $428.27M | $623.04M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $434.11M | (m) | $633.45M | $813.15M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $430.75M | (m) | $787.51M | $1.01B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $103.14M | (m) | $599.61M | $781.52M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $102.61M | (m) | $837.66M | $1.08B | (m) |
| 2021-03-31 | (m) | (m) | $3.65M | $90.76M | (m) | $919.12M | $1.09B | (m) |
| 2020-12-31 | (m) | (m) | $1.46M | $92.42M | (m) | $607.09M | $703.59M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $93.39M | (m) | $710.68M | $787.69M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $92.91M | (m) | $840.94M | $905.23M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $92.42M | (m) | $905.17M | $989.80M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $91.79M | (m) | $545.99M | $631.68M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $75.02M | (m) | $536.05M | $640.53M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $54.51M | (m) | (m) | $464.94M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |